一种由脂肪醇修饰的新型低密度脂蛋白吸附剂的制备及性能

研究了以花生壳膳食纤维为载体,以十二醇为原料,引入了疏水基团的新型低密度脂蛋白(LDL)吸附剂的制备。结果表明,该吸附剂可使血浆总胆固醇(TC)吸附率达到62.7%,低密度脂蛋白胆固醇(LDL-C)吸附率达到78.1%,对高密度脂蛋白胆固醇(HDL-C)的吸附率为28.4%。该吸附剂对低密度脂蛋白具有良好的吸附选择性。     

辛伐他汀临床治疗高脂血症效果观察

目的了解辛伐他汀用于临床治疗高脂血症的效果。方法选择高脂血症患者25例,服用辛伐他汀10～20mg,每日1次,晚间顿服,疗程8周。观察用药前后血浆总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白固醇(LDL—C)的水平变化。结果对TC的有效率达91.5%,对TG、HDL-C和LDL-C的有效率分别为76.2%、72.2%和82.5%;治疗前后血脂水平变化有统计学意义。结论辛伐他汀可作为治疗高血脂的一种有效、安全的理想药物。     

磺酸基降解黄原胶选择性清除血浆LDL/Fib的研究

以黄原胶为原料,进行酸降解,再以3-氯-2-羟基丙磺酸钠为磺化试剂,在适当的条件下进行磺化反应,获得降解黄原胶磺化衍生物。考察降解黄原胶相对分子质量以及3-氯-2-羟基丙磺酸钠用量对产物磺酸基含量的影响,确立较优化的磺化反应条件。以降解黄原胶磺化衍生物为净化剂,研究其选择清除血浆中低密度脂蛋白(LDL)及纤维蛋白原(Fib)的性能。结果表明,在pH=5.10,净化剂浓度为2500 mg/L时,可使血浆总胆固醇(TC)下降45%左右,低密度脂蛋白胆固醇下降24%,纤维蛋白原清除近100%,而对总蛋白和高密度脂蛋白(HDL)影响较小。     

胆固醇在高脂高胆固醇诱导非酒精性脂肪性肝炎发生发展过程中的动态作用

目的探讨胆固醇在高脂高胆固醇诱导的非酒精性脂肪性肝炎(non-alcoholic steatohepatitis,NASH)发生发展过程中的动态作用。方法将SD大鼠随机分为CON组(正常饮食)、HFC0组(20%脂肪)、HFC1组(20%脂肪+1%胆固醇)、HFC2组(20%脂肪+2%胆固醇)及HFC5组(20%脂肪+5%胆固醇)。饲喂第4、6、8及12周末,采血并取肝脏组织;采用油酸(oleic acid,OA)及OA+低密度脂蛋白-胆固醇(low-density lipoprotein-cholesterol,LDL-C)诱导人肝脏正常细胞(HL-7702)5 d后,构建NASH模型,同时以RPMI1640培养基(含10%FBS)为对照组。分别检测大鼠血浆及HL-7702细胞培养液中丙氨酸氨基转移酶(ALT)和天门冬氨酸氨基转氨酶(AST)的含量,大鼠肝脏组织及HL-7702细胞中总胆固醇(total cholesterol,TC)及甘油三酯(triglyceride,TG)的含量;HE及Masson染色观察肝脏组织病理改变;油红O及菲律宾菌素染色观察HL-7702细胞内脂滴及胆固醇含量;Western blot法检测活性n-固醇调节元件结合蛋白-2(n-sterol regulatory element binding protein 2,n-SREBP-2)、低密度脂蛋白受体(low-density lipoproteins receptors,LDLR)及3-羟基3-甲基戊二酰辅酶A还原酶(3-hydroxy-3-methylglutaryl-CoA reductase,HMGCR)的蛋白表达水平。结果动物水平:12周末,与CON组比较,HFC2组、HFC5组血浆中ALT、AST及肝脏组织中TC、TG含量均显著升高(P均<0.05),肝细胞脂肪变性、气球样变性及纤维化病变明显,HFC2组、HFC5组大鼠NASH诱导成功;经Western blot分析,4、6及8周末,HFC2组、HFC5组较CON组LDLR蛋白表达水平均显著升高(P均<0.05),12周末,HFC5组较CON组LDLR蛋白表达水平显著降低(P<0.05);4、6及8周末,各组n-SREBP-2蛋白表达水平与CON组比较差异均无统计学意义(P均>0.05),12周末,HFC2组、HFC5组较CON组n-SREBP-2蛋白表达水平均显著升高(P均<0.05);4、6及12周末各组HMGCR蛋白表达水平与CON组比较差异均无统计学意义(P均>0.05),8周末,HFC5组较CON组HMGCR蛋白表达水平显著降低(P<0.05)。细胞水平:OA+LDL-C组较对照组及OA组细胞内胆固醇含量、n-SREBP-2及HMGCR蛋白表达水平均显著升高(P均<0.05);OA组及OA+LDL-C组较对照组LDLR蛋白表达水平均显著降低(P均<0.05)。结论胆固醇摄入量和摄入时间的长短与NASH肝损伤呈正相关;胆固醇可诱导肝细胞高表达LDLR,促使胆固醇进入肝脏增加,抑制HMGCR调控的内源性胆固醇合成;随着肝内胆固醇堆积增多,肝细胞LDLR表达减少,使肝内胆固醇相对不足,反馈性调节n-SREBP-2及HMGCR表达升高,打破肝脏胆固醇代谢稳态,促进了NASH的发生发展。     

阿托伐他汀的调脂疗效和安全性的临床研究

目的探讨阿托伐他汀的调脂疗效及临床的安全性。方法将86例确诊为冠心病,血清总胆固醇TC>5.2mmol/L(200mg/L)或LDL-C>3.12mmol/L(120mg/L)或合并TG>117mmol/L(150mg/L)的患者,随机分成两组:A组(治疗组)42例口服阿托伐他汀10mg/d;B组(对照组)44例口服辛伐他汀,20mg/d,两组同治疗8周。于服药前、服药后第8周分别测定甘油三酯(TG)、血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)等指标。结果治疗8周后,两组患者TC、TG和LDL-C均下降,阿托伐他汀使得TG下降幅度42.5%,TC下降幅度34.5%,LDL-C下降幅度40.9%;辛伐他汀TG使得下降幅度39.6%,TC下降幅度32%,LDL-C下降幅度39.7%;两组的有效率分别为95.2%和93.2%。两组间各指标相比差异无统计学意义(P>0.05)。且两组无明显的不良反应,患者治疗后肝功能、肾功能、心肌酶等均无明显改变。结论阿托伐他汀治疗高脂血症的疗效显著,具有良好的安全性,值得在临床进一步推广。     

改性龙眼壳对废水中六价铬离子的吸附研究

采用硫酸溶液对龙眼壳进行改性制备吸附剂,研究吸附剂粒径、废水浓度、吸附时间和温度等因素对吸附率的影响。结果表明,改性吸附剂吸附Cr(Vl)的最佳pH为2.0、离子浓度为30 mg/L、吸附时间为100 min时,吸附率可达到99%左右。改性吸附剂对Cr(Vl)的吸附符合准二级动力学方程,经过5级静态吸附后,吸附率仍可以达到83.39%。用HCl溶液(1+5)对吸附后的改性龙眼壳可解吸再生,改性龙眼壳可作为含铬废水的处理材料。     

高锰酸钾改性活性炭的表征及吸附Cr(Ⅵ)性能的研究

用KMnO_4改性活性炭对重金属离子Cr(Ⅵ)进行吸附。采用扫描电子显微镜(SEM)、傅里叶变换红外光谱仪(FT-IR)、N2吸附/解吸等方法对改性活性炭的理化性质进行表征,探讨各种参数(如pH、接触时间、吸附剂用量、温度和初始浓度)对吸附Cr(Ⅵ)的影响。研究证明,当pH 2时,KMnO_4改性活性炭对重金属离子Cr(Ⅵ)的吸附效果最佳,AC1和AC3吸附率分别达到65%和90%以上,而未改性AC0的吸附率约40%。随着pH的增加,吸附效果变弱。接触时间为4 h时,KMnO_4改性活性炭对重金属离子Cr(Ⅵ)的吸附基本达到平衡,而温度对其影响不大。当改性炭的投加量为50 mg、Cr(Ⅵ)溶液浓度为10 mg/L时,吸附效果最佳,AC3的吸附率可达90%以上,比AC0增加50%以上。改性活性炭吸附Cr(Ⅵ)过程符合准二级动力学方程。     

丝瓜络对废水中二价铜离子的吸附研究

研究丝瓜络对二价铜离子的吸附效果。研究发现吸附时间、吸附剂用量、p H值、Cu(Ⅱ)初始浓度对丝瓜络的吸附容量和吸附率都有影响。在相同的吸附条件下,天然丝瓜络的吸附容量和吸附率均高于经酸处理的改性丝瓜络。在25℃,溶液中Cu(Ⅱ)初始浓度为20 mg/L,模拟废水体积为10 m L,p H为4,吸附时间40 min,吸附剂用量为0.1 g的吸附条件下,天然丝瓜络对Cu(Ⅱ)的吸附率达到77.70%,酸处理的改性丝瓜络吸附率只有51%。     

人参煎方对2型糖尿病大鼠糖代谢及脂代谢的影响

目的:研究人参煎方对2型糖尿病大鼠糖脂代谢的影响。方法:SD大鼠高糖高脂饲料喂养4周后,结合腹腔注射链脲佐菌素(STZ)_35mg·kg~(-1),建立2型糖尿病大鼠模型,将成模的大鼠按血糖随机分为模型组,阳性对照组(盐酸二甲双胍0.15 g·kg~(-1)·d~(-1)),人参煎方高、中、低剂量组(按生药量计为3.76,1.88,0.94 g·kg~(-1)·d~(-1)),并设正常对照组。给药3周后,观察治疗期间大鼠的一般情况,检测空腹血糖(FBG),糖化血清蛋白(GSP),血清甘油三酯(TG),总胆固醇(CHO),高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)的含量。结果:与正常组比较,模型组大鼠血糖,糖化血清蛋白含量明显增高(P0.01),血清甘油三酯(TG),总胆固醇(CHO),低密度脂蛋白胆固醇(LDL-C)含量增高(P0.05),高密度脂蛋白胆固醇(HDL-C)含量明显下降(P0.05)。人参煎方可降低2型糖尿病大鼠的FBG、GSP、TG、CHO及LDL-C的含量,提高HDL-C的水平,与模型组比较有明显改善(P0.05),人参煎方与盐酸二甲双胍药物治疗组无显著性差异。结论:人参煎方能有效地降低2型糖尿病大鼠的血糖,纠正糖尿病大鼠脂代谢紊乱,调节血脂。     

辛伐他汀调脂作用临床观察

目的观察辛伐他汀对高脂血症患者降脂治疗有效性和安全性。方法对60例高脂血症患者予晚间服辛伐他汀,剂量20mg,共8周,观察用药前后血浆总胆固醇、甘油三酯、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、谷丙转氨酶水平变化。结果治疗4周和8周后TG、TC、LDL-C均较前明显下降(P<0.01),HDL-C明显提高(P>0.05),治疗前后ALT无明显变化,整个治疗过程的严重不良反应有:2例出现轻微的ATL升高,占6.7%,停药后1周复查恢复正常。治疗前后尿素氮、肌酐及CPK无显著变化。不良反应轻,未出现肝功能、肾功能改变或加重的情况,能持续用药。结论辛伐他汀对高脂血症患者降脂治疗是有效和安全的。     

Synthesis and characterization of heparin immobilized PAN-based resin

Summary The role of low-density lipoprotein cholesterol (LDL-C) as a major risk factor for coronary heart disease (CHD) is well established [1-5]. Hemoperfusion treatment for familial hyperlipidemia (FH) and serious cardiovascular diseases is currently employed when the reduction of low-density lipoprotein (LDL) in patient’s plasma concentration appears impossible to be achieved by diet or drugs administration [6.7]. Since late 1970s, many scientists have been engaged in developing different kinds of adsorbents which included non-specific, selective adsorbents and immunoadsorbents [8]. Up to date, Polyacrylate coated polyacrylamide (DALI) extracorporeal LDL apheresis [9.10], and heparin-induced extracorporeal LDL apheresis Precipitation [11] had been developed. Most of the LDL adsorbents were used in plasma for the removal of LDL-C and a primarycell/plasma separation by a centrifuge or a membrane separator was required [12]. So far no corresponding observation was reported for the heparin immobilized PAN-based resin. In this paper, the resin was synthesized and the properties or factors affecting its adsorption were investigated.     

Interaction between dietary proteins and lipids in the regulation of serum and liver lipids in the rabbit. Effect of fish protein

Purified diets varying in dietary protein, namely casein (CA), soy protein (SP), fish protein (FP), and lipid origin (corn oil (CN), coconut oil (CO)) were fed to rabbits to evaluate the effects of protein and fat source, as well as protein-lipid interactions, on serum total, lipoprotein and hepatic lipid levels. Dietary proteins and lipids exerted a separate effect on serum total cholesterol (C), very low-density lipoprotein cholesterol (VLDL-C), and low-density lipoprotein cholesterol to high density lipoprotein cholesterol (LDL-C/HDL-C) ratio. Hence, CA increased serum cholesterol compared to SP, while coconut oil enhanced serum and VLDL-C, and decreased LDL-C/HDL-C compared to corn oil. Dietary proteins interacted with dietary lipids to modulate HDL-C levels. Thus, FP maintained a high level of HDL-C regardless of lipid origin, compared to CA and SP whose HDL-C levels were decreased by corn oil, compared to coconut oil. A dietary protein-lipid interaction was also observed in the regulation of liver cholesterol levels. Coconut oil, compared to corn oil, decreased liver cholesterol in rabbits fed FP, whereas hepatic cholesterol concentration was unaltered by dietary lipid source in CA- and SP-fed rabbits. These results demonstrate that dietary proteins act synergistically with dietary lipids to regulate cholesterol metabolism in the rabbit. This work was presented in part at the 74th Annual FASEB meeting held in Washington, D.C., April 1–5, 1990.     

Lipidemic effects of an interesterified mixture of butter, medium-chain triacylglycerol and safflower oils

The objective of this study was to determine if the positional structure of dietary triacylglycerol affected lipidemic responses. Thirty healthy adults (16 men and 14 postmenopausal women) with low-density lipoprotein cholesterol (LDL-C) concentrations >3.37 mM (130 mg/dl) enrolled in a prospective, single-blind, cross-over outpatient clinical trial that consisted of two 5-wk dietary phases. After baseline screening, subjects were instructed to follow individualized meal plans (weight maintenance diets with 36% of total energy from fat, half of which was from a test oil) and randomized to receive either butter (B) or an interesterified mixture (IM) of butter, medium-chain triacylglycerol (MCI), and safflower oils. Blood drawn during weeks 5 and 10 of feeding was analyzed for total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), LDL-C, and triacylglycerols (TAG). Mean plasma levels of TC (B, 6.98±1.06 mM; IM, 7.09±1.20 mM), HDL-C (B,1.30±0.35 mM; IM, 1.29±0.34 mM), and LDL-C (B, 4.91±0.95 mM; IM, 492±1.10 mM) were not significantly different between the two dietary treatments. Mean TAG levels were higher for the interesterified B-MCT mixture (B, 1.75±0.72 mM; IM, 1.96±0.86 mM, P<0.05). We conclude that an IM of B, MCT and safflower oils as compared to native B has no appreciable effect on plasma cholesterol concentrations but is associated with a modest rise in plasma TAG.     

Effects of dressing containing plant sterol on serum cholesterol concentration and the safety evaluation in borderline or mildly hypercholesterolemic Japanese subjects

In a placebo-controlled double-blind study, we examined the effects of dressing containing plant sterol (PS) on blood lipids and the safety in Japanese borderline or mildly hypercholesterolemic subjects. Fifty-nine subjects [total cholesterol (TC) concentration > or = 200 mg/dL] were randomly divided into two groups and were given daily 15 g of dressing containing 800 mg of PS [PS(+)-group] or without PS [PS(-)-group] for 12 weeks. Every 4 weeks, fasting blood was examined and subjective symptoms were analyzed. Serum TC, low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (ApoB) concentrations did not change in the PS(-)-group, while TC and ApoB significantly decreased in the PS(+)-group at 8 and 12 weeks and LDL-C at 4, 8 and 12 weeks. Moreover, serum TC, LDL-C and ApoB concentrations were significantly lower than those of PS(-)-group at 8 and 12 weeks. Other laboratory tests were all in normal ranges and no adverse events were observed. The results indicated that PS-containing dressing decreased serum TC, LDL-C and ApoB concentrations in borderline or mildly hypercholesterolemic subjects. It is therefore proved that the dressing containing PS is helpful in maintaining blood cholesterol level normal and hence, the health of Japanese.     

Lipoprotein Subfraction Profile and HDL-Associated Enzymes in Sickle Cell Disease Patients

Although hypocholesterolemia is a reported finding in sickle cell disease (SCD), low-density lipoprotein (LDL)/high-density lipoprotein (HDL) subfractions and HDL-associated enzymes have not been determined in SCD patients. Blood was collected from 38 hemoglobin (Hb)A volunteers and 45 homozygous HbSS patients who had not received blood transfusions in the last 3 months. Serum lipids were measured by automated analyzer while LDL and HDL subfraction analysis was done by continuous disc polyacrylamide gel electrophoresis. Serum levels of cholesteryl ester transfer protein (CETP), lecithin-cholesterol acyltransferase (LCAT), apolipoprotein B (apoB) and apolipoprotein A-1 (apoA-I) were determined by enzyme-linked immunosorbent assay (ELISA). Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) levels were significantly decreased, while TG levels were significantly increased in SCD patients compared to controls. A significant decrease in intermediate-density lipoprotein (IDL)-C, IDL-B, IDL-A and LDL-1 fractions were seen in SCD patients, while no significant difference was observed in small dense LDL particles. A significant decrease was seen in HDL-large, HDL-intermediate and HDL-small fractions in SCD patients versus controls. Levels of LCAT and ApoA-1 protein measured in SCD patients were significantly lower while no significant difference was observed in CETP and ApoB protein levels compared to controls. The reduction observed in LDL- and HDL-C in SCD patients was reflected as significantly decreased IDL, LDL-1 and HDL-subfractions. Decreased HDL subfractions may possibly lead to the reduced ApoA-1 and LCAT protein levels observed in SCD patients.     

Minimal effective dose on serum cholesterol concentration and the safety evaluation of dressing containing plant sterol in Japanese subjects

We examined the minimal effective dose on serum cholesterol concentration and the safety of dressing containing plant sterol in humans. EXP.1: Sixty-eight healthy Japanese males (total cholesterol (TC) > or = 170 mg/dL) were randomly divided into four groups, and were given 0, 400, 800 or 1200 mg/day of plant sterol in 15 g dressing for 4 weeks followed by the washout period of 4 weeks. Although there were no significant differences in serum TC and low-density lipoprotein cholesterol (LDL-C) concentrations among all groups after feeding plant sterol for 4 weeks, in 36 subjects with TC > or = 220 mg/dL, serum LDL-C concentration tended to reduce when received 800 or 1200 mg of plant sterol, and the difference between 0 and 1200 mg groups was statistically significant. The difference between 0 and 800 mg groups was near significant (p=0.053). Intake of 400 mg of plant sterol did not change serum LDL-C concentration. EXP.2: Twenty-one healthy Japanese subjects (TC > or = 180 mg/dL, 10 men, 11 women) were given 2400 mg/day of plant sterol in 45 g dressing for 4 weeks. Clinical data were all remained normal. These results indicated that minimal effective dose of the plant sterol on serum cholesterol concentration in healthy male subjects is around 800 mg/day, and intake of 2400 mg/day of plant sterol is regarded to be safe.     

A Cross-sectional Study on the Relationship Between Homocysteine and Lipid Profiles Among Chinese Population from Hunan

Previous studies have explored the relationship between homocystein (Hcy) and lipid profiles. However, the results from these studies have been inconsistent. The current study investigated the correlation between Hcy and lipid profiles in Chinese community-based population. The participants were composed of 4012 Chinese people aged 30–92 years old, who were recruited from rural and urban communities in the Hunan Province. Non-parametric test and logistic regression were used to examine the distribution of Hcy and lipid profiles (triglyceride [TG], total cholesterol [TC], low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C]) and the relationship between them. The median age of subjects was 54.50 years old, and 40.98% were male. Median Hcy was 13.20 μmol/L, and 35.39% had hyperhomocysteinemia (HHcy). Median TG was 1.51 mmol/L, TC was 4.77 mmol/L, LDL-C was 2.62 mmol/L, and HDL-C was 1.27 mmol/L. In multivariable logistic regression analysis, HHcy was associated with high levels of TG (OR_male = 2.240, p < 0.001; OR_female = 2.539, p < 0.001), TC (OR_male = 2.237, p < 0.001; OR_female = 2.202, p < 0.001), and LDL-C (OR_male = 1.413, p = 0.010; OR_female = 1.617, p < 0.001) in the different sexes population and low level of HDL-C in females (OR = 1.326, p = 0.023) after adjusting for confounders. HHcy was independently associated with an increasing risk of low HDL-C among females. The regression analysis showed that HHcy was also associated with hypertriglyceridemia, hypercholesterolemia, and high level of LDL-C in males and females from Chinese community-based population, which provides a basis for the treatment and prevention of abnormal lipid metabolism.     

A Single Nucleotide Polymorphism in the Stromal Cell-Derived Factor 1 Gene Is Associated with Coronary Heart Disease in Chinese Patients

Coronary heart disease (CHD) is highly prevalent globally and a major cause of mortality. Genetic predisposition is a non-modifiable risk factor associated with CHD. Eighty-four Chinese patients with CHD and 253 healthy Chinese controls without CHD were recruited. Major clinical data were collected, and a single nucleotide polymorphism (SNP) in the stromal cell-derived factor 1 (SDF-1) gene at position 801 (G to A, rs1801157) in the 3''-untranslated region was identified. The correlation between rs1801157 genotypes and CHD was evaluated by a multivariate logistic regression analysis. The allele frequency in the CHD and control groups was in Hardy-Weinberg equilibrium (HWE) (p > 0.05). The frequency of the GG genotype in the CHD group (59.5%) was significantly higher than that in the control group (49.8%) (p = 0.036). A number of variables, including male sex, age, presence of hypertension, and the levels of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), uric acid, and total bilirubin, were associated with CHD in a primary univariate analysis. In a multivariable logistic regression analysis, the GG genotype (GG:AA, odds ratio (OR) = 2.31, 95% confidence interval (CI) = 1.21–5.23), male sex, advanced age (≥60 years), presence of hypertension, LDL-C level ≥ 3.33 mg/dL, HDL-C level < 1.03 mg/dL, and TG level ≥ 1.7 mg/dL were independent risk factors for CHD.     

Association of Dietary Phytosterols with Cardiovascular Disease Biomarkers in Humans

Cardiovascular disease (CVD) is a leading cause of death worldwide. Elevated concentrations of serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) are major lipid biomarkers that contribute to the risk of CVD. Phytosterols well known for their cholesterol-lowering ability, are non-nutritive compounds that are naturally found in plant-based foods and can be classified into plant sterols and plant stanols. Numerous clinical trials demonstrated that 2 g phytosterols per day have LDL-C lowering efficacy ranges of 8–10%. Some observational studies also showed an inverse association between phytosterols and LDL-C reduction. Beyond the cholesterol-lowering beneficial effects of phytosterols, the association of phytosterols with CVD risk events such as coronary artery disease and premature atherosclerosis in sitosterolemia patients have also been reported. Furthermore, there is an increasing demand to determine the association of circulating phytosterols with vascular health biomarkers such as arterial stiffness biomarkers. Therefore, this review aims to examine the ability of phytosterols for CVD risk prevention by reviewing the current data that looks at the association between dietary phytosterols intake and serum lipid biomarkers, and the impact of circulating phytosterols level on vascular health biomarkers. The clinical studies in which the impact of phytosterols on vascular function is investigated show minor but beneficial phytosterols effects over vascular health. The aforementioned vascular health biomarkers are pulse wave velocity, augmentation index, and arterial blood pressure. The current review will serve to begin to address the research gap that exists between the association of dietary phytosterols with CVD risk biomarkers.